[KASID指南：溃疡性结肠炎的药物治疗（2026年）]。
完整摘要 · 中文译文
溃疡性结肠炎（UC）是一种慢性免疫介导的炎症性肠病，其治疗格局不断扩展，临床复杂性日益增加。本指南由韩国肠道疾病研究协会（KASID）制定，旨在为韩国成人UC患者的药物治疗提供更新的、基于证据的推荐意见。指南制定采用了GRADE-ADOLOPMENT方法，并使用AGREE II对源指南进行评估。关键问题采用PICO框架构建，评估了2017年至2025年间发布的源指南和共识文件，并在PubMed、Embase、Cochrane Library和KoreaMed中进行了覆盖2020年1月至2026年4月的针对性文献检索。本指南涵盖轻中度及中重度UC的诱导和维持治疗、急性重症UC的管理、手术指征、生物类似药和皮下制剂的使用，以及治疗优化和序贯治疗。推荐意见基于结构化证据回顾和证据到决策（Evidence-to-Decision）考量制定，并通过改良德尔菲共识流程和外部评审最终确定。最终推荐强调客观的疾病控制、个体化治疗选择、急性重症UC中及时升级治疗或手术，以及基于疗效、安全性、合并症、既往治疗暴露、患者偏好、药物可及性和韩国医疗环境的共同决策。本指南旨在支持一致、实用且以患者为中心的UC管理实践。 以患者为中心的护理，并改善溃疡性结肠炎（UC）成人患者的长期预后。
完整摘要 · 英文原文
Ulcerative colitis (UC) is a chronic immune-mediated inflammatory bowel disease with an expanding therapeutic landscape and increasing clinical complexity. This guideline was developed by the Korean Association for the Study of Intestinal Diseases (KASID) to provide updated, evidence-based recommendations for the medical management of adult patients with UC in Korea. Guideline development used the GRADE-ADOLOPMENT approach, with source guidelines appraised using AGREE II. Key questions were formulated using the PICO framework, source guidelines and consensus documents published from 2017 through 2025 were appraised, and targeted literature searches covering January 2020 through April 2026 were conducted in PubMed, Embase, the Cochrane Library, and KoreaMed. The guideline addresses induction and maintenance therapy for mild-to-moderate and moderate-to-severe UC, management of acute severe UC, indications for surgery, use of biosimilars and subcutaneous formulations, and treatment optimization and sequencing. Recommendations were formulated based on structured evidence review and Evidence-to-Decision considerations, and were finalized through a modified Delphi consensus process and external review. The final recommendations emphasize objective disease control, individualized treatment selection, timely escalation or surgery in acute severe UC, and shared decision-making based on efficacy, safety, comorbidities, prior treatment exposure, patient preference, drug accessibility, and the Korean healthcare context. This guideline is intended to support consistent, practical, and patient-centered care and to improve long-term outcomes for adults with UC.